Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)

NCT02107365 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER_GOV

Sponsor class

Conditions

Hepatitis C Virus Genotype 4 Infection

Interventions

DRUG: Asunaprevir
DRUG: Daclatasvir
DRUG: Ribavirin
DRUG: Pegylated Interferon alpha-2a

Sponsor

ANRS, Emerging Infectious Diseases

Collaborators

[object Object]